精神病症状和TDP-43病理在肌缩侧面硬化症
Yuki Suzuki1, Tadashi Adachi2, Kentaro Yoshida1
1Division of Neurology, Department of Brain and Neurosciences, Faculty of Medicine, Tottori University, Yonago, Japan.
Journal of the neurological sciences
|September 26, 2024
概括
肌缩侧面硬化症 (ALS) 的精神症状与特定的神经病理变化有关,特别是某些大脑区域的TDP-43病理. 这表明ALS患者这些非运动症状的潜在神经病理基础.
科学领域:
- 神经病理学神经病理学
- 神经科学是一个神经科学.
- 肌缩侧面硬化症 (ALS) 研究研究
背景情况:
- 肌缩侧面硬化症 (ALS) 越来越被认为是一种复杂的疾病,不仅仅涉及运动神经元退化.
- 在ALS患者中经常观察到认知障碍和精神症状,但其潜在的神经病理基础仍然不明.
研究的目的:
- 调查ALS尸检病例中精神症状与特定神经病理发现之间的关联.
- 探索TDP-43病理学和其他神经病理学标记在ALS精神症状的表现中的作用.
主要方法:
- 对15例尸检确认的ALS病例进行临床病理学分析.
- 在九个大脑区域中,对TDP-43病理负担的半定量评估,按形态分类 (包容,神经细胞,点,质包容).
- 评估神经纤维状结,粉状斑块,莱维体和形粒.
主要成果:
- 在15名ALS患者中,有7人表现出精神症状.
- 在患有精神症状的患者中,在包括尖,内腔皮层和海马体在内的大脑区域观察到显著更高的TDP-43病理学得分.
- 神经细胞质内含,缩性神经炎和点在精神病症状组中更为普遍,而认知障碍与TDP-43病理负担没有显著相关.
结论:
- 在ALS中,精神症状可能与TDP-43病理有关,特别是在穿孔通路内.
- 这一发现突出了ALS精神表现的潜在神经病理基质,与运动神经元退化不同.
更多相关视频
06:58Evaluation of LC3-II Release via Extracellular Vesicles in Relation to the Accumulation of Intracellular LC3-positive Vesicles
Published on: October 18, 2024
600
13:31Novel Atomic Force Microscopy Based Biopanning for Isolation of Morphology Specific Reagents against TDP-43 Variants in Amyotrophic Lateral Sclerosis
Published on: February 12, 2015
8.8K
相关概念视频
01:15Parkinson's Disease: Overview
495
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
495
01:26Alzheimer's Disease: Overview
451
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
451
01:37Neural Regulation
39.2K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.2K
01:22Alzheimer's Disease: Treatment
170
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
170
03:03Amyloid Fibrils
9.3K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.3K